Research Article
Correlations among PPAR, DNMT1, and DNMT3B Expression Levels and Pancreatic Cancer
Table 1
Clinical and pathological features of patients with pancreatic ductal adenocarcinoma (PDAC).
| | PDAC | |
| | Age at diagnosis, median () | 69 (42ā81) | | Duration of follow-up, median () | 18.48 (8.16ā53.11) | | Gender, male/female (%male) | 25/5 (83) | | Tumour localization, (%) | | | āHead | 28 (93) | | āBody-tail | 2 (7) | | Tumour type, (%) | | | āAdenocarcinoma | 24 (80) | | āAdenocarcinoma mucinous | 6 (20) | | Tumour grading, (%) | | | āG1: well differentiated | 4 (13) | | āG2: moderately differentiated | 16 (54) | | āG3: poorly differentiated | 10 (33) | | T: Tumour size, (%) | | | āT2 | 5 (17) | | āT3 | 25 (83) | | N: regional lymph nodes, (%) | | | āN0 | 7 (23) | | āN1 | 23 (77) | | Lymph nodes ratio, median () | 0.13 (0.00ā0.80) | | Tumour stage, (%) | | | āIIA | 7 (23) | | āIIB | 23 (77) | | Perineural invasion, (% ) | 9/21 (30) | | Margins of resection, (%) | | | āR0: negative rection margins | 22 (27) | | āR1: microscopic positive resection margins | 8 (73) |
|
|
Pancreatic cancer staging. āExocrine and endocrine pancreas.ā In [25].
|
